In a report released yesterday, Steven Valiquette from Barclays maintained a Hold rating on DENTSPLY SIRONA Inc (NASDAQ: XRAY), with a price target of $41. The company’s shares closed yesterday at $39.41, close to its 52-week low of $38.83.
According to TipRanks.com, Valiquette is a 4-star analyst with an average return of 9.5% and a 56.5% success rate. Valiquette covers the Services sector, focusing on stocks such as WellCare Health Plans, Molina Healthcare, and Owens & Minor.
Currently, the analyst consensus on DENTSPLY SIRONA Inc is a Hold with an average price target of $43.33, a 10.0% upside from current levels. In a report released yesterday, Robert W. Baird also downgraded the stock to Hold with a $38 price target.
.
See today’s analyst top recommended stocks >>
Based on DENTSPLY SIRONA Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $1.12 billion. In comparison, last year the company had a GAAP net loss of $1.05 billion.
Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is neutral on the stock. Most recently, in June 2018, Michael J. Coleman, a Director at XRAY sold 6,038 shares for a total of $265,503.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DENTSPLY SIRONA, Inc. engages in the design, manufacture, sales, and distribution of professional dental products and technologies. It operates through the Technologies and Equipment and Consumables segments.